4D Molecular Therapeutics Inc., of Emeryville, Calif., said it closed a $90 million series B financing led by Viking Global Investors. The proceeds will be used to advance its therapeutic vector evolution platform and pipeline of next-generation adeno-associated virus (AAV) gene therapeutics. The company's lead intravitreally delivered AAV gene therapy asset for choroideremia is expected to enter clinical trials next year.